MCID: UTR058
MIFTS: 53

Uterine Anomalies

Categories: Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Uterine Anomalies

MalaCards integrated aliases for Uterine Anomalies:

Name: Uterine Anomalies 57
Uterine Diseases 53 41 43 71
Uterine Disease 11 14
Uterine Abnormality 53
Uterine 75

Characteristics:


Inheritance:

Autosomal dominant 57

Classifications:



External Ids:

Disease Ontology 11 DOID:345
OMIM® 57 192000
ICD9CM 34 621.9
MeSH 43 D014591
NCIt 49 C26907
SNOMED-CT 68 237068005
ICD10 31 N85.9
MedGen 40 C0266383
SNOMED-CT via HPO 69 31401003
UMLS 71 C0042131

Summaries for Uterine Anomalies

MedlinePlus: 41 The uterus, or womb, is the place where a baby grows when a woman is pregnant. The first sign of a problem with the uterus may be bleeding between periods or after sex. Causes can include hormones, thyroid problems, fibroids, polyps, cancer, infection, or pregnancy. Treatment depends on the cause. Sometimes birth control pills treat hormonal imbalances. If a thyroid problem is the cause, treating it may also stop the bleeding. If you have cancer or hyperplasia, an overgrowth of normal cells in the uterus, you may need surgery. With two other uterine problems, tissue that normally lines the uterus grows where it is not supposed to. In endometriosis, it grows outside the uterus. In adenomyosis, it grows in the uterus's outside walls. Pain medicine may help. Other treatments include hormones and surgery.

MalaCards based summary: Uterine Anomalies, also known as uterine diseases, is related to uterine sarcoma and uterine corpus cancer, and has symptoms including pelvic pain An important gene associated with Uterine Anomalies is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are miRNAs involved in DNA damage response and Interactions between immune cells and microRNAs in tumor microenvironment. The drugs Doxycycline and Ergometrine have been mentioned in the context of this disorder. Affiliated tissues include uterus, cervix and lymph node, and related phenotype is bicornuate uterus.

Disease Ontology: 11 A female reproductive system disease that is located in the uterus.

More information from OMIM: 192000

Related Diseases for Uterine Anomalies

Diseases in the Uterine Anomalies family:

Uterine Inflammatory Disease

Diseases related to Uterine Anomalies via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2132)
# Related Disease Score Top Affiliating Genes
1 uterine sarcoma 33.1 ESR1 CYP19A1
2 uterine corpus cancer 32.9 MIR139 H2AC18 ESR1
3 endometrial stromal sarcoma 32.3 H2AC18 ESR1 CYP19A1
4 uterine benign neoplasm 32.3 MIR199A1 ESR1 CYP19A1
5 cervix disease 32.2 MIR9-1 MIR518A1 MIR361 MIR34A MIR214 MIR21
6 endometrial disease 32.2 MIR200A MIR141 ESR1
7 placenta disease 32.0 MIR518D MIR199A1 H2AC18
8 cervix carcinoma 32.0 MIR9-1 MIR214 MIR21 MIR200A MIR199A1 MIR196A1
9 breast cancer 31.5 MIR9-1 MIR34A MIR214 MIR21 MIR200A MIR199A1
10 renal cell carcinoma, nonpapillary 31.5 MIR9-1 MIR361 MIR34A MIR214 MIR21 MIR200A
11 lymphoma, hodgkin, classic 31.4 MIR9-1 MIR21 MIR200A H2AC18
12 diffuse large b-cell lymphoma 31.4 MIR9-1 MIR214 MIR21 MIR199A1 MIR196A1 MIR17
13 hypertension, essential 31.3 MIR9-1 MIR518D MIR361 MIR34A MIR214 MIR21
14 vascular disease 31.3 MIR214 MIR21 MIR199A1 MIR145 MIR143 ESR1
15 ovarian disease 31.3 MIR9-1 MIR518A1 MIR34A MIR214 MIR21 MIR200A
16 lynch syndrome 31.3 MIR17 MIR139 H2AC18 ESR1
17 kidney cancer 31.3 MIR214 MIR21 MIR199A1 MIR17 MIR145 MIR142
18 lymphoma, non-hodgkin, familial 31.2 MIR9-1 MIR518A1 MIR361 MIR34A MIR214 MIR21
19 rectum cancer 31.2 MIR214 MIR21 MIR200A MIR17 MIR145 MIR143
20 human papillomavirus infectious disease 31.1 MIR21 MIR199A1 MIR196A1 MIR142 MIR139
21 leukemia, acute myeloid 31.1 MIR9-1 MIR361 MIR34A MIR21 MIR199A1 MIR196A1
22 gastrointestinal stromal tumor 31.1 MIR518A1 MIR199A1 H2AC18 ESR1
23 kidney disease 31.1 MIR21 MIR200A MIR199A1 MIR141 HNF1B ESR1
24 rectal benign neoplasm 31.1 MIR17 MIR145 MIR143
25 endometriosis of ovary 31.1 MIR9-1 MIR199A1 MIR145 MIR141 MIR139 HNF1B
26 ewing sarcoma 31.1 MIR9-1 MIR214 MIR199A1 H2AC18
27 immune deficiency disease 31.1 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
28 ovarian serous carcinoma 31.1 MIR214 MIR21 MIR200A MIR199A1 MIR145 MIR143
29 bladder cancer 31.1 MIR21 MIR200A MIR199A1 MIR17 MIR145 MIR143
30 type 2 diabetes mellitus 31.0 MIR9-1 MIR34A MIR214 MIR21 MIR199A1 MIR196A1
31 gastric cancer 31.0 MIR9-1 MIR34A MIR214 MIR21 MIR199A1 MIR196A1
32 leukemia, acute lymphoblastic 31.0 MIR9-1 MIR214 MIR21 MIR199A1 MIR196A1 MIR17
33 body mass index quantitative trait locus 11 31.0 MIR9-1 MIR34A MIR214 MIR21 MIR199A1 MIR196A1
34 endometriosis 30.9 MIR200A MIR199A1 MIR17 MIR145 MIR143 MIR142
35 peripheral nervous system disease 30.9 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
36 connective tissue disease 30.9 MIR9-1 MIR518A1 MIR361 MIR34A MIR214 MIR21
37 cervix small cell carcinoma 30.9 MIR199A1 MIR145 MIR143
38 skin melanoma 30.9 MIR21 MIR200A MIR199A1 H2AC18
39 respiratory failure 30.9 MIR21 MIR199A1 MIR17 MIR142 H2AC18
40 ovarian clear cell carcinoma 30.9 MIR9-1 MIR21 MIR199A1 HNF1B H2AC18
41 lung cancer susceptibility 3 30.9 MIR9-1 MIR214 MIR21 MIR200A MIR199A1 MIR196A1
42 lung cancer 30.8 MIR9-1 MIR518A1 MIR361 MIR34A MIR214 MIR21
43 lipid metabolism disorder 30.8 MIR21 MIR199A1 MIR17 H2AC18
44 lymphatic system disease 30.8 MIR9-1 MIR518A1 MIR34A MIR214 MIR21 MIR199A1
45 hematologic cancer 30.8 MIR9-1 MIR518A1 MIR34A MIR214 MIR21 MIR199A1
46 ovary adenocarcinoma 30.8 MIR196A1 MIR17 H2AC18 ESR1
47 lymphangioma 30.7 MIR200A MIR199A1 MIR143 H2AC18
48 leukemia, chronic lymphocytic 30.7 MIR9-1 MIR34A MIR214 MIR21 MIR199A1 MIR196A1
49 esophageal cancer 30.7 MIR9-1 MIR361 MIR34A MIR214 MIR21 MIR200A
50 myelodysplastic syndrome 30.7 MIR9-1 MIR34A MIR199A1 MIR17 MIR142 H2AC18

Graphical network of the top 20 diseases related to Uterine Anomalies:



Diseases related to Uterine Anomalies

Symptoms & Phenotypes for Uterine Anomalies

Human phenotypes related to Uterine Anomalies:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 bicornuate uterus 30 HP:0000813

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
G U:
uterine anomalies
uterus arcuatus
uterus bicornis unicollis

Clinical features from OMIM®:

192000 (Updated 08-Dec-2022)

UMLS symptoms related to Uterine Anomalies:


pelvic pain

Drugs & Therapeutics for Uterine Anomalies

Drugs for Uterine Anomalies (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 599)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
2
Ergometrine Approved Phase 4 60-79-7 443884
3
Azithromycin Approved Phase 4 83905-01-5 447043
4
Lymecycline Approved, Investigational Phase 4 992-21-2
5
Tetracycline Approved, Vet_approved, Withdrawn Phase 4 60-54-8 5353990
6
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
7
Dydrogesterone Approved, Investigational, Withdrawn Phase 4 152-62-5 9051
8
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
9
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887
10
Ferrous fumarate Approved Phase 4 141-01-5
11
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
12
Racephedrine Approved, Experimental Phase 4 299-42-3, 90-82-4, 90-81-3 5032 9294 7028
13
Phenylephrine Approved Phase 4 59-42-7 6041
14
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
15
Tranexamic acid Approved Phase 4 1197-18-8 5526
16
Calcium carbonate Approved, Investigational Phase 4 471-34-1
17
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
18
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
19
Mecobalamin Approved, Investigational Phase 4 13422-55-4
20
Zinc oxide Approved Phase 4 1314-13-2
21
Tocopherol Approved, Investigational Phase 4 1406-66-2
22
Mefenamic acid Approved Phase 4 61-68-7 4044
23
Butorphanol Approved, Illicit, Vet_approved Phase 4 58786-99-5, 42408-82-2 5361092
24
Plasminogen Approved Phase 4 9001-91-6
25
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
26
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
27
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
28
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
29
Chloroprocaine Approved, Investigational Phase 4 133-16-4 8612
30
Naproxen Approved, Vet_approved Phase 4 22204-53-1 156391 1302
31
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
32
Mepivacaine Approved, Vet_approved Phase 4 96-88-8, 1722-62-9 4062
33
Norethisterone Approved Phase 4 68-22-4 199472 6230
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
35
Iron Approved Phase 4 7439-89-6 29936
36
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
37
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
38
Cefazolin Approved Phase 4 25953-19-9 33255
39
Prilocaine Approved Phase 4 721-50-6 4906
40
Methylergometrine Approved Phase 4 113-42-8 8226
41
Carboprost tromethamine Approved Phase 4 58551-69-2 35023177
42
Dinoprost tromethamine Approved, Vet_approved Phase 4 38562-01-5
43
Dinoprost Approved, Investigational Phase 4 551-11-1 5283078 5280363
44
Medroxyprogesterone acetate Approved, Investigational Phase 4 520-85-4, 71-58-9 6279 10631
45
Ethinylestradiol Approved Phase 4 57-63-6 5991
46
Desogestrel Approved Phase 4 54024-22-5 40973
47
Goserelin Approved Phase 4 65807-02-5 5311128 47725
48
Dienogest Approved Phase 4 65928-58-7 13175121 68861
49
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
50
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971

Interventional clinical trials:

(show top 50) (show all 2750)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Self-cross-linked Hyaluronic Acid Gel in the Prevention of Intrauterine Adhesions After Second Trimester Abortion Unknown status NCT02868437 Phase 4
2 Continuous Pre-uterine Wound Infiltration Versus Intrathecal Morphine for Postoperative Analgesia After Cesarean Section. Controlled Comparative Study. Unknown status NCT02279628 Phase 4 Ropivacaine;Morphine
3 Vaginal Misoprostol Versus Bilateral Uterine Artery Ligation in Decreasing Blood Loss in Trans-abdominal Myomectomy , a Randomized Control Trail Unknown status NCT02643186 Phase 4 preoperative vaginal misoprostol
4 Multicenter Randomized Clinical Trial to Evaluate the Safety and Effectiveness of Cavaterm TM Thermal Balloon Endometrial Ablation in Women With Dysfunctional Uterine Bleeding Compared to Transcervical Resection of the Endometrium (TCRE) Unknown status NCT00549159 Phase 4
5 PERCING : Ovarian Drilling Versus Ovarian Stimulation + Intra Uterine Insemination (IUI) + Metformin in the PCOS (PolyCystic Ovaries Syndrome) Treatment Unknown status NCT00378729 Phase 4 Metformin and FSHr
6 Comparison Between Natural Progesterone and Vaginal Pessary for the Prevention of Spontaneous Preterm Birth in Pregnant Women With a Uterine Cervix Measuring 25 mm or Less in Length Unknown status NCT02511574 Phase 4 natural progesterone
7 Ulipristal Acetate Versus GnRH Analogue for Myometrial Preservation in Patients With Submucosal Uterine Leiomyoma G2 Unknown status NCT02357563 Phase 4 ulipristal acetate;Leuprolide acetate
8 Treatment of Prolonged Uterine Bleeding of Etonogestrel (ENG)-Releasing Implant Using Norethisterone (NET)-Only Pill: a Randomized Controlled Trial Unknown status NCT04047875 Phase 4 Norethisterone 10mg/day;Placebo
9 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
10 Comparing Oxytocin and Oxytocin-ergometrine Combinations for Increasing Uterine Tone in Cesarean Delivery: a Pharmacokinetic-pharmacodynamic Study. Unknown status NCT01236482 Phase 4 Oxytocin versus oxytocin-ergometrine
11 Safety and Efficacy of High Intensity Focused Ultrasound Ablation Compared With Myomectomy in Uterine Fibroids:A Randomized Controlled Study Unknown status NCT01239641 Phase 4
12 ED90 Determination of Carbetocin for the Prevention of Postpartum Uterine Atony in Women Undergoing an Elective Cesarean Delivery Unknown status NCT01579201 Phase 4 Carbetocin
13 A Randomized Control Trial of Combined Vaginal Misoprostol and Perivascular Vasopressin During Robotic Myomectomy Unknown status NCT03815344 Phase 4 Standard;Standard-vaginal misoprostol
14 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
15 Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia? Unknown status NCT00842738 Phase 4
16 A Randomized Controlled Trial Study, To Compare Colporrhaphy Versus NAZCA TC™ ,Macroporous Polypropylene Mesh, In Surgical Treatment To Greater Anterior Vaginal Prolapse . Unknown status NCT00676325 Phase 4
17 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
18 A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer Unknown status NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
19 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
20 Study of Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Antibiotic Treatment Unknown status NCT01661985 Phase 4 Azithromycin;Doxycycline;lymecycline
21 Randomized Double-blind Placebo Controlled Trial to Assess the Role of Intrauterine Cornual Block (ICOB) in Combination With Direct Cervical Block in Outpatient Endometrial Ablation Completed NCT01808898 Phase 4
22 Ulipristal Acetate Therapy Versus Uterine Artery Embolization in Management of Uterine Fibroids Completed NCT04832906 Phase 4 Ulipristal Oral Tablet
23 A Prospective, Randomized, Single-Center Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
24 The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids Completed NCT00995878 Phase 4
25 A Comparison Between Continuous Infusion vs. Patient Controlled Intraabdominal Injection of Local Anesthetics for Treatment of Postoperative Pain After Abdominal Hysterectomy. A Randomized, Double-blind Study. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
26 A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates. Completed NCT01953107 Phase 4
27 Efficacy and Safety of Different Doses of Vaginal Misoprostol Prior to Intra Uterine Contraceptive Device Insertion Completed NCT04273984 Phase 4 Misoprostol
28 Randomized Controlled Trial of IV Nitroglycerin in Cesarean Deliveries After Second Stage Arrest for the Prevention of Uterine Extension Completed NCT02265965 Phase 4 intravenous nitroglycerin
29 Phase IV Study of Flurbiprofen Axetil for Uterine Contraction Pain After Abortion Completed NCT00725218 Phase 4 Saline;Flurbiprofen Axetil
30 Study of Special Guided Training Model on Insertion Techniques for Postplacental Intra Uterine Device to Prevent Expulsion Completed NCT02054195 Phase 4
31 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization : a Single-center Prospective Randomized Study Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
32 Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids. Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
33 Tranexamic Acid Versus Novel Uterine Cooling Technique in Reducing Blood Loss and Incidence of Postpartum Hemorrhage at Caesarean Section Completed NCT02780245 Phase 4 Tranexamic Acid
34 Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Dydrogesterone + Multivitamin Nature in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
35 Up-down Determination of the ED90 of Oxytocin Infusions for the Prevention of Postpartum Uterine Atony in Parturients Undergoing Cesarean Delivery Completed NCT00785395 Phase 4 Oxytocin infusion
36 Efficacy of Magnesium and Alpha Lipoic Acid Supplementation in Reducing Premature Uterine Contractions Completed NCT02016495 Phase 4 Placebo
37 Buffered Lidocaine for Paracervical Block to Decrease Injection Pain During First Trimester Uterine Aspirations Completed NCT03107754 Phase 4 Lidocaine;Lidocaine-Sodium Bicarbonate
38 Pain Perception and Side Effects During Sonohysterography With Balloon Catheters: a Randomized Comparative Study of Cervical With Uterine Catheter Placement Completed NCT01936116 Phase 4
39 A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Completed NCT03886220 Phase 4 Elagolix;Placebo
40 Propofol-butorphanol Combined Anesthesia During Uterine Curettage on Abortion Completed NCT00795314 Phase 4 Fentanyl Citrate;Butorphanol Tartrate
41 A Prospective, Randomized, Single Blind, Two Arms Controlled Study to Confirm the Safety and Verify Performance of the IUB™ SCu300A Intrauterine Device in Comparison to TCu380 IUD Intra-uterine Contraceptive Device Completed NCT02036177 Phase 4
42 A Multicentre, Open Label, Uncontrolled Study of the Tolerance, Acceptability and Contraceptive Efficacy of Mirena 52 mg®, an Intra-uterine Levonorgestrel Device, During the First Year After Insertion Post-partum Completed NCT00696202 Phase 4 Mirena (BAY86-5028)
43 Prospective Randomized Trial of Tranexamic Acid Versus Levonorgestrel Intrauterine System for the Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Completed NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
44 Comparison of the Effectiveness of 3 Different Dose Regimens of Oxytocin in Preventing Uterine Atony and Postpartum Hemorrhage During Vaginal Delivery Completed NCT00790062 Phase 4 Oxytocin
45 Phase 4 Study of Magnetic Resonance Guided Focused Ultrasound Surgery Following Gonadotrophin Releasing Hormone Agonist Treatment for Symptomatic Uterine Fibroids Completed NCT00159328 Phase 4
46 Intra-uterine Injection of Human Chorionic Gonadotrophin Before Embryo Transfer in ICSI Completed NCT01030393 Phase 4 human chorionic gonadotrophin
47 Comparison of Two Doses of Carbetocin for Prevention of Uterine Atony During Elective Cesarean Section: a Randomized Controlled Trial Completed NCT01630187 Phase 4 Carbetocin
48 Effect of Metformin With or Without Folate Addiction on Uterine Blood Flow and Trophoblastic Invasion in Pregnant Patients With Polycystic Ovary Syndrome Completed NCT01115140 Phase 4 metformin plus placebo;Metformin plus folic acid;placebo plus folic acid;placebo alone
49 Effects of Tranexamic Acid on Post Partum Hemorrhage by Uterine Atony After Cesarean Section Delivery: a Randomized, Placebo Controlled Trial. Completed NCT01599468 Phase 4 Tranexamic Acid;saline serum
50 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole

Search NIH Clinical Center for Uterine Anomalies

Inferred drug relations via UMLS 71 / NDF-RT 50 :


CARBOXYMETHYLCELLULOSE CALCIUM

Cochrane evidence based reviews: uterine diseases

Genetic Tests for Uterine Anomalies

Anatomical Context for Uterine Anomalies

Organs/tissues related to Uterine Anomalies:

FMA: Uterus
MalaCards : Uterus, Cervix, Lymph Node, Thyroid, Breast, Placenta, Bone Marrow

Publications for Uterine Anomalies

Articles related to Uterine Anomalies:

(show top 50) (show all 1357)
# Title Authors PMID Year
1
Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer. 62 41
36441547 2022
2
Androgen Signaling in Uterine Diseases: New Insights and New Targets. 62 41
36358974 2022
3
Familial bicornuate and double uterus. 57
4841581 1974
4
[On the problem of frequent familial occurrence of uterus abnormalities]. 57
5997716 1966
5
Observations on the results of pregnancies in women resident in Belfast. II. Abortions, hydatidiform moles and ectopic pregnancies. 57
13834545 1959
6
Congenital abnormalities of the uterus and pregnancy. 57
13316096 1956
7
UTERUS DIDELPHYS. 57
20320870 1938
8
The link between intrauterine adhesions and impaired reproductive performance: a systematic review of the literature. 41
36376829 2022
9
Oestrogen receptor-alpha gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata. 53 62
11139535 2001
10
ECC-1 human endometrial cells as a model system to study dioxin disruption of steroid hormone function. 53 62
10478797 1999
11
Expression of estrogen receptor variants in normal and neoplastic human uterus. 53 62
8735603 1996
12
Surgical management of a congenital genital tract abnormality in a patient with Lynch syndrome. 62
36460312 2022
13
Vaginal progesterone for the prevention of preterm birth: who can benefit and who cannot? Evidence-based recommendations for clinical use. 62
36475431 2022
14
Use of Two Levonorgestrel Intrauterine Devices in a Patient with a Uterus Didelphys: A Case Report. 62
35820604 2022
15
The association between congenital uterine anomalies and perinatal outcomes - does type of defect matters? 62
34238096 2022
16
Evaluation of complications, conversion rate, malignancy rate, and, surgeon's experience in laparoscopic assisted supracervical hysterectomy (LASH) of 1274 large uteri: A retrospective study. 62
36203317 2022
17
In vitro effects of cinnamon, oregano, and thyme essential oils against Escherichia coli and Trueperella pyogenes isolated from dairy cows with clinical endometritis. 62
36413866 2022
18
Role of Genital Tract Bacteria in Promoting Endometrial Health in Cattle. 62
36422307 2022
19
Pegbovigrastim treatment resulted in an economic benefit in a large randomized clinical trial in grazing dairy cows. 62
36460504 2022
20
Prepartum heat stress in dairy cows increases postpartum inflammatory responses in blood of lactating dairy cows. 62
36460497 2022
21
Intrauterine infusion of a pathogenic bacterial cocktail is associated with the development of clinical metritis in postpartum multiparous Holstein cows. 62
36400620 2022
22
Effect of VD3 on cell proliferation and the Wnt signaling pathway in bovine endometrial epithelial cells treated with lipopolysaccharide. 62
36156426 2022
23
Hysteroscopicmetroplasty as a treatment option for women with congenital dysmorphic uterus suffering from impaired reproductive performance. 62
36377644 2022
24
Limitations of imaging screening tests in the detection of incomplete uterine septum or arcuate uterine anomaly. 62
35315517 2022
25
CA125 as a predictor of endometrial cancer lymphovascular space invasion and lymph node metastasis for risk stratification in the preoperative setting. 62
36396713 2022
26
Current chemotherapeutic options for the treatment of gestational trophoblastic disease. 62
36399723 2022
27
Cracking the enigma of adenomyosis: an update on its pathogenesis and pathophysiology. 62
36099328 2022
28
Study on Preoperative Neutrophil/Lymphocyte (NLR) and Platelet/Lymphocyte Ratio (PLR) as a Predictive Factor in Endometrial Cancer. 62
36308354 2022
29
Prevalence of subclinical endometritis in dairy cows that recovered after treatment of clinical endometritis with cephapirin and PGF2α. 62
36108547 2022
30
Reproductive and ICSI outcomes after hysteroscopic metroplasty for T-shaped uterus, a prospective follow up study. 62
35914707 2022
31
Transient non-cyclical activity of external myometrium should be considered to avoid errors in diagnosis of adenomyosis and uterine anomalies. 62
34985801 2022
32
The effect of hysteroscopic metroplasty on fertility in T-shaped and Y-shaped dysmorphic uterus. 62
35727192 2022
33
What type of uterine anomalies had an additional effect on pregnancy outcomes, compared to other uterine anomalies? An evaluation of a large population database. 62
36216352 2022
34
Research on acute phase proteins and inflammatory cytokines biomarkers in dromedary camels (Camelus dromedarius) with clinical endometritis. 62
36282373 2022
35
Effect of calving season on metritis incidence and bacterial content of the vagina in dairy cows. 62
35970030 2022
36
Long-term Experience of Single-port and Multi-port Total Laparoscopic Hysterectomy in a Single Center. 62
36099098 2022
37
Factors Associated with the Severity of Clinical Mastitis. 62
36297146 2022
38
Icariin Alleviates Escherichia coli Lipopolysaccharide-Mediated Endometritis in Mice by Inhibiting Inflammation and Oxidative Stress. 62
36142129 2022
39
Effectiveness of a Modified Administration Protocol for the Medical Treatment of Feline Pyometra. 62
36288130 2022
40
Progesterone supplementation to improve fertility of selected subgroups of lactating cows during the summer and fall. 62
35582955 2022
41
Accuracy to Predict the Onset of Calving in Dairy Farms by Using Different Precision Livestock Farming Devices. 62
35953995 2022
42
Staphylococcus aureus-Induced Necroptosis Promotes Mitochondrial Damage in Goat Endometrial Epithelial Cells. 62
36077938 2022
43
How do bicornuate uteri alter pregnancy, intra-partum and neonatal risks? A population based study of more than three million deliveries and more than 6000 bicornuate uteri. 62
35946504 2022
44
A Comparative Analysis of Nondescent Vaginal Hysterectomy, Laparoscopy-Assisted Vaginal Hysterectomy, and Total Laparoscopic Hysterectomy for Benign Uterine Diseases at a Rural Tertiary Care Center. 62
36158288 2022
45
Preliminary application of three-dimensional printing in congenital uterine anomalies based on three-dimensional transvaginal ultrasonographic data. 62
35836228 2022
46
Surgical disorders in pediatric and adolescent gynecology: Vaginal and uterine anomalies. 62
35880405 2022
47
Primary characteristics and outcomes of newly diagnosed low-grade endometrial stromal sarcoma. 62
35641004 2022
48
Peroxisome proliferator-activated receptor expression in the canine endometrium with cystic endometrial hyperplasia-pyometra complex. 62
35373395 2022
49
Quantitative assessment of iteratively denoised 3D SPACE with inner-volume excitation and simultaneous multi-slice BLADE for optimizing female pelvis magnetic resonance imaging at 1.5 T. 62
35871059 2022
50
First report on clinical aspects, blood profiles, bacterial isolation, antimicrobial susceptibility, and histopathology in canine pyometra in Thailand. 62
36185522 2022

Variations for Uterine Anomalies

Expression for Uterine Anomalies

Search GEO for disease gene expression data for Uterine Anomalies.

Pathways for Uterine Anomalies

GO Terms for Uterine Anomalies

Cellular components related to Uterine Anomalies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.74 MIR9-1 MIR361 MIR214 MIR21 MIR200A MIR199A1
2 extracellular vesicle GO:1903561 9.26 MIR34A MIR214 MIR21 MIR17

Biological processes related to Uterine Anomalies according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.92 ESR1 MIR17 MIR199A1 MIR21 MIR214 MIR34A
2 negative regulation of inflammatory response GO:0050728 9.87 MIR199A1 MIR145 MIR142 MIR141
3 negative regulation of cell migration GO:0030336 9.85 MIR9-1 MIR34A MIR214 MIR21 MIR145
4 miRNA-mediated gene silencing GO:0035195 9.8 MIR139 MIR141 MIR142 MIR143 MIR145 MIR17
5 negative regulation of osteoblast differentiation GO:0045668 9.79 MIR9-1 MIR214 MIR17
6 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.78 MIR214 MIR21 MIR17
7 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.72 MIR361 MIR199A1 MIR196A1
8 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.71 MIR145 MIR199A1 MIR21
9 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.71 MIR9-1 MIR21 MIR17 MIR145
10 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.65 MIR34A MIR214 MIR21
11 negative regulation of angiogenesis GO:0016525 9.63 MIR361 MIR34A MIR214 MIR21 MIR145 MIR143
12 angiotensin-activated signaling pathway GO:0038166 9.62 MIR145 MIR143
13 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.6 MIR21 MIR17
14 aorta smooth muscle tissue morphogenesis GO:0060414 9.59 MIR145 MIR143
15 negative regulation of lamellipodium assembly GO:0010593 9.58 MIR214 MIR196A1
16 positive regulation of metalloendopeptidase activity GO:1904685 9.58 MIR21 MIR17
17 negative regulation of BMP secretion GO:2001285 9.56 MIR214 MIR17
18 positive regulation of connective tissue replacement GO:1905205 9.54 MIR34A MIR214 MIR199A1
19 regulation of phenotypic switching GO:1900239 9.52 MIR145 MIR143
20 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.51 MIR17 MIR143
21 positive regulation of cellular response to hypoxia GO:1900039 9.49 MIR21 MIR145
22 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.43 MIR145 MIR143
23 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.43 MIR214 MIR199A1 MIR17
24 negative regulation of vascular endothelial growth factor production GO:1904046 9.26 MIR361 MIR34A MIR199A1 MIR17

Molecular functions related to Uterine Anomalies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.73 MIR9-1 MIR361 MIR34A MIR214 MIR21 MIR199A1
2 mRNA base-pairing translational repressor activity GO:1903231 9.5 MIR9-1 MIR518A1 MIR361 MIR34A MIR214 MIR21

Sources for Uterine Anomalies

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....